![Logo](https://i0.wp.com/agenparl.eu/wp-content/plugins/Plugin%20Logo/Agenparl.png?w=788&ssl=1)
(AGENPARL) – mer 03 luglio 2024 Lund, Sweden, July 3, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA),
will publish its interim report for January-June 2024 on July 18, 2024.
Interested parties may join the Company’s quarterly conference call on the same
date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren Tulstrup,
President and CEO, Matthew Shaulis, CCO and US President, Evan Ballantyne, CFO,
and Hitto Kaufmann, CR&DO. The call will include a review of the interim results
and a business and pipeline update. It will be held in English.
Slides used in the presentation will be made available on the company website at
the following link: Financial
reports (https://www.hansabiopharma.com/investors/financial-reports/).
To participate in the telephone conference, please use the dial-in details
provided below:
Sweden: +46-8-1241-0952
United States: +1 646-787-0157
Participant access code: 765135
The webcast will be available on https://hansabiopharma.eventcdn.net/events/half
-year-january-june-2024
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at http://www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/EXRfWCRd2QifvFqRevW7tCR85VYLP7aA6mdcpCjyNE9qXfXhT7FXi2iGFUbwmcZqF5rne5BFzH9Wp5Xow8CALv3sa9FA1a1Nd8MCigH6Pzs4Q.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/EXRfWCRd2QifvFqRevW7tCR85VYLP7aA6mdcpCjyNE9qXfXhT7FXi2iGFUbwmcZqF5rne5BFzH9Wp5Xow8CALv3sa9FA1a1Nd8MCigH6Pzs4Q.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden